A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

Academic Article

Abstract

  • Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell- associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Landry ML; Stanat S; Biron K; Brambilla D; Britt W; Jokela J; Chou S; Drew WL; Erice A; Gilliam B
  • Start Page

  • 688
  • End Page

  • 692
  • Volume

  • 44
  • Issue

  • 3